



Wallflower (*Erysimum cheiri* (L.) Crantz) from Past to Future

Ghazaleh Mosleh¹, Parmis Badr^{2,3}, Amir Azadi^{3,4}, Zohreh Abolhassanzadeh³, Seyed Vahid Hosseini⁵, Abdolali Mohagheghzadeh^{1,3*}

¹Department of Phytopharmaceuticals (Traditional Pharmacy), Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

²Phytopharmaceutical Technology and Traditional Medicine Incubator, Shiraz University of Medical Sciences, Shiraz, Iran.

³Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

⁴Department of Pharmaceutics, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

⁵Colorectal Research Center, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Wallflower (*Erysimum cheiri* (L.) Crantz) is a common medicinal plant in Persian medicine and nowadays some traditional products from wallflower are consumed on global markets. The aim of the present study was to study the phytochemical constituents of wallflower and discuss safety evaluations related to the traditional wallflower preparations. Major Persian scholars (e.g. Avicenna) books, Persian manuscripts (e.g. Makhzan-al-advia) and Arabic medical manuscripts (e.g. Alshamel-fi alsanaat altebya) of the medieval Islamic era as well as current search engines including Pubmed, Scopus, Siencedirect, and Google Scholar were included in the study from 1700 up to 2018 A.D. In traditional medicine manuscripts, various topical and oral dosage forms of wallflower were administered in low doses. After renaissance, phytochemical investigations reported cardiac steroids in wallflower and it might be the reason that next medical investigations on the herb have been interrupted. According to in vivo studies, topical indications of cardiac steroids in doses lower than their inhibitory concentration 50 (IC₅₀) should be safe and effective in some cutaneous disorders. Wallflower is reported to have several different classes of compounds including: 11 types of cardenolides (such as strophanthidin, bipindogenin, uzarigenin, cannogenol and digitoxigenin derivatives), two flavonoids, a cyanidin and two glucosinolates. Therefore, for safety guarantee, wallflower products require dose adjustment based on IC₅₀ and probable cardenolide soluble content in that dosage forms.

Keywords: *Erysimum cheiri*; phytochemistry; wallflower

Citation: Mosleh G, Badr P, Azadi A, Abolhassanzadeh Z, Hosseini SV, Mohagheghzadeh A. Wallflower (*Erysimum cheiri* (L.) Crantz) from past to future. Res J Pharmacogn. 2019; 6(2): 85-95.

Introduction

Wallflower (*Erysimum cheiri* (L.) Crantz), synonyms: *Cheiranthus cheiri* L. from Brassicaceae family [1], is a common medicinal plant in Persian medicine (PM) while, it is not popular in modern medicine. Wallflower is an ornamental herb which is native to Europe, especially Mediterranean region and is extensively cultivated around the world [2]. It is a perennial herb that grows up to 25-80 cm (figure

1). Botanically, the leaves are lanceolate shaped and are 5-10 cm in long, the flowers have four sepals and six stamens [3] have a pleasant fragrance and are arranged in dense racemes. The color of flowers is golden yellow to orange yellow. The fruit is a silique which has distinct ribs and the seeds are arranged in one row [4]. The inner surface of the fruit has trichomes and on its valves are usually 4-5-rayed, few 3-rayed,

* Corresponding author: mohaghegh@sums.ac.ir

and infrequently 6-7-rayed [5]. Seeds are sub-orbicular, pale brown and about 3 mm long [3]. Wallflower description in the traditional medical manuscripts is in agreement with the above botanical description [6-12]. Some traditional preparations are available in global herbal markets containing wallflower as an ingredient. Because of cardiotoxic constituents of wallflower organs, toxicity and safety of corresponding products should be mentioned in detail [13-27]. This study has been conducted to provide information on phytochemistry, traditional and current medicinal properties of wallflower preparations and it emphasizes the necessity of safety considerations for wallflower products.



Figure 1. Wallflower (*Erysimum cheiri* (L.) Crantz)
(photographed by authors)

Methods

PM literature including, “Al hawi”, the Canon of medicine, “Tohfeh al- momenin”, “Makhzan-al-advia” and “Mohit-e azam” as well as medicinal manuscript from Arabian scholars i.e.: “Alshamel-fi alsanaat altebya”, “Hadiqat ol-azhar” were searched with terms of cheir-e zard and cheir-e asfar [6-12]. Main part of this study was performed via electronic search on Pubmed, Scopus, Siencedirect, and GoogleScholar with terms of *Cheiri*, *Erysimum*, *Cheiranthus*, wallflower and goldlack (German common name), from 1700 up to 2018 A.D. History of

phytochemical investigations on wallflower was provided and summarized in a diagram according to available articles [13-27]. Drawing of the molecular structures was done by ChemDraw Pro 8.0 software.

Results and Discussion

Wallflower from past to present

A brief history of wallflower investigations has been demonstrated in figure 2. Wallflower was well known as a medicinal plant in Persian and Arabic medical manuscripts of the medieval Islamic era [6-12]. Later, a large number of studies have been directed on phytochemical studies of wallflower [13-27]. In 1899, an isolated cardiac glycoside (cheiranthin) was introduced as a new remedy extracted from wallflower [17]. In 1932, in vivo toxicological studies on cheiranthin made some safety concerns [22]. Cheiranthin and cheirinine were reported as wallflower chemical compounds in the early phytochemical investigations [14]; however, they has not been identified as pure chemical compounds by current phytochemistry In 1994, a review on wallflower cardiac glycosides [25]. And in 2001, a pharmacological in vivo study on wallflower were published. It introduced wallflower as a medicinal plant which was used clinically in some skin diseases [26]. Based on Persian and Arabic medical manuscripts of the medieval Islamic era, various wallflower dosage forms have different medicinal effects. Wallflower had oral, topical and vaginal but no parenteral indications in Persian medicine. Topical dilute decoction of the flower was recognized as a good remedy for aphthous and inflammations. Topical oil of flower has been reported as analgesic, anti-inflammation and hair tonic. Cerate dosage form is suggested as anti-fissure (both anal and skin fissure) and wound healer. Root in a topical decoction or poultice has been reported as analgesic and anti-inflammatory agent. The seeds in the form of sitz bath or vaginal suppository have been administered as emmenagogue, abortifacient and labor inducer [6-12]. Nowadays, wallflower preparations are available in herbal markets for traditional medicine requests. In Iran, there is a traditional medicine ointment compound from *E. cheiri* and *Helianthus annuus* which is used for anal fissure treatment [28]. In Indian markets there is a multi-component tablet containing wallflower for breastfeeding mothers to improve lactation [29].




Figure 2. A brief history of wallflower investigations

In traditional societies of present India, wallflower is still used as an abortifacient agent [30]. In Indian medicine, flowers are recommended as cardioactive, antispasmodic, purgative, emmenagogue, deobstruent and tonic. Besides, wallflower seeds are known as stomachic, diuretic, expectorant, but goitrogenic, and the extracts of leaves and the seeds are antibacterial [31]. Wallflower is used as cardioactive, emmenoguge, fertilizer and anti-paralysis agent in Pakistan [32]. The leaves and flowers are listed in herbal ingredients of “Asian medicines”, which are used in west as fertilizer agent, anti-paralysis, emmenagogue, cardiotoxic and expectorant [33]. In German phytotherapy, the dried flowers as well as the seeds and roots are considered to be anti-itching, emmenoguge, fertilizer and anti-tumor [34].

Phytochemistry of wallflower

According to literature, different parts of the herb have special profiles of compounds. Table 1 has explained chemical composition of wallflower organs in details. Molecular structures of wallflower chemical compounds have been presented in figure 1.

Wallflower pharmacology and toxicology

Despite the safety concerns, there is no report of health hazard or side effects about oral administration of wallflower [4,42]. Dried flowers, dried ripe seeds and fresh aerial parts of the plant before flowering, are reported to have medicinal properties as internal drops, infusion and multi-component preparations. Infusion is

permitted in the form of mixing 2-3 g dried flower in 100 mL water (3-4 cups daily) [4]. Although oral administration of wallflower is considered to have low resorption rate (absorption into the circulation of cells or tissue), its parenteral dosage form is considered to have strong efficacy and probably poisoning effects [4]. According to European Food Safety Authority (EFSA) cheirotoxin (cardiotonic and antineoplastic agent) is a chemical of concern [13,35]. In addition to cheirotoxin, cheirosid A and glucocheirolin are categorized as moderately hazardous compounds [35,43] and wallflower is identified to have cytotoxic action [44]. Hazard and toxicity of cheiroside A is described by lethal dose of 0.681 mg/kg in cats by intravenous administration, and lethal dose of cheiroline is reported as 3-7 mg/kg in Mus (a subgenus of the rodent genus) by intravenous administration [13]. There is a suspect for goitrogenic properties of cheiroline [45]. In vitro, cheiroline increases activation and expression of Nrf2 as well as expression of hemeoxygenase 1 and γ -glutamylcysteine. In addition, cheiroline is an antibacterial and antifungal agent. Also in vitro anti-bacterial effects of cheiroline on *H. pylori* has been proved [13,46,47]. The minimum lethal dose of cheiranthin for the frog has been reported to be 2.2×10^{-7} g/g [22]. Cheiranthin showed the characteristics of systolic rest in frogs [48]. Wallflower root intravenously applied in anaesthetized rabbits has resulted in obvious vasodilation and bradycardia that eventually led to the animal's death [49].

Table 1. Natural components from wallflower

No.	Compounds and molecular formula	Plant part(s)	References
Terpenoides			
- Cardenolides			
(1)	Cheirotoxin (C ₃₅ H ₅₂ O ₁₅)	Seed, Aerial parts	[4,35]
(2)	Deglucocheirotoxin (C ₂₉ H ₄₂ O ₁₀)	Seed	[25]
(3)	Erysimoside (C ₃₃ H ₅₂ O ₁₄)	Seed	[4,25]
(4)	Glucosylerysimoside (C ₄₁ H ₆₂ O ₁₉)	Seed	[4]
(5)	Alliside (C ₂₉ H ₄₄ O ₁₀)	Seed	[25]
(6)	Glucosylalliside (C ₃₆ H ₅₆ O ₁₅)	Seed	[25]
(7)	Glucobipindogulomethylsido (C ₃₅ H ₅₄ O ₁₅)	Seed	[25]
(8)	Cheiroside A (C ₃₅ H ₅₄ O ₁₃)	Seed	[4]
(9)	Neouzarin (C ₃₅ H ₅₄ O ₁₄)	Seed	[25,36]
(10)	Erycordin (C ₃₅ H ₅₄ O ₁₄)	Seed	[25]
(11)	Digifucocellobioside (C ₄₁ H ₆₄ O ₁₈)	Seed	[25]
-Monoterpenoids			
(12)	Geraniol: 3,7-Dimethyl-2,6-octadien-1-ol (C ₁₀ H ₁₈ O) (<i>E</i>) form	Essential oil of flower	[37]
(13)	Nerol: 3,7-Dimethyl-2,6-octadien-1-ol (C ₁₀ H ₁₈ O) (<i>Z</i>) form	Essential oil of flower	[37]
(14)	Linalool (C ₁₀ H ₁₈ O)	Essential oil of flower	[37]
Phenylpropanoids			
-Flavonoids			
(15)	Isorhamnetin (C ₁₆ H ₁₂ O ₇)	Herb	[13]
(16)	Isorhamnetin 3,7-diglycosides (C ₂₇ H ₃₀ O ₁₅)	Herb	[13]
(17)	Kaempferol (C ₁₅ H ₁₀ O ₆)	Flower	[31]
-Cyanidins			
(18)	Cyanidin 3,5-diglycosides (C ₄₁ H ₄₅ O ₂₂ ⁻¹)	Flower	[27,38]
- Others			
(19)	Anis aldehyde (C ₈ H ₈ O ₂)	Essential oil of flower	[37]
(20)	Benzyl alcohol (C ₇ H ₈ O)	Essential oil of flower	[37]
(21)	Salicylic acid (C ₇ H ₆ O ₃)	Essential oil of flower	[37]
Glucosinolates and isothiocyanates			
(22)	Cheiriline (C ₅ H ₉ NO ₂ S ₃)	Essential oil of flower, seed, leaf, fruit, flower	[4,19,40]
(23)	Glucocheirolin (C ₁₁ H ₂₁ NO ₁₁ S ₃)	Seed	[41]
(24)	Iberin (C ₅ H ₉ NOS ₂)	Seed	[4]
(25)	Glucosylberin (C ₁₁ H ₂₁ NO ₁₀ S ₃)	Seed	[4]
(26)	Ibervirin	Seed	[13]
Miscellaneous nitrogen containing groups			
(27)	Choline (C ₅ H ₁₄ NO)	Seed	[15]
(28)	Anthranilic acid (C ₇ H ₇ NO ₂)	Essential oil of flower	[39]
Aliphatics			
(29)	Acetic acid (CH ₃ COOH)	Essential oil of flower	[37]
(30)	Palmitic acid (C ₁₆ H ₃₂ O ₂)	Seed	[39]
(31)	Lignoceric acid (C ₂₄ H ₄₈ O ₂)	Seed	[39]
(32)	Linolenic acid (C ₁₈ H ₃₀ O ₂)	Seed	[39]
(33)	Oleic acid (C ₁₈ H ₃₄ O ₂)	Seed	[39]

Toxicity concerns of cardiac glycosides are due to inhibition of Na⁺ K⁺ ATPase mechanism. There are various factors affecting the amount of cardenolide absorption in transdermal indications. Area and nature of wound are two important parameters responsible for cardenolide toxicity. Also cutaneous circulation, frequency, duration and formulation characteristics are other parameters affecting absorption of cardenolides [50]. On the other hand, application of cardenolide containing herbs in dermal dosage forms has a profound history [8,51]. Topical application of cardenolides in the safe doses lower than their inhibitory concentration 50% (IC₅₀) could accelerate dermal collagen synthesis [52]. An in vivo study on wallflower has shown anti-tumor properties of topical wallflower extract on murine skin. It has introduced wallflower as a medicinal plant, used clinically in some skin diseases like inflammations [26].

Conclusion


In Persian and Arabic medical manuscripts of the medieval Islamic era, various topical dosage forms of wallflower (in low doses) have been recommended for wound healing, analgesic and anti-inflammatory purposes. Although parenteral rout of administration was not suggested in traditional medicine, oral or vaginal dosage forms mostly have been indicated for emmenoguge, abortifacient and anti-endometriosis activities [6-12]. Phytochemical investigations have reported some cardiac glycosides from wallflower organs and concomitantly safety concerns of medicinal application of the herb fell into a doubt [17,22]. Probably it became the reason that wallflower is not popular in current medicine. Nowadays, there are some traditional medicine preparations around the world, still applying wallflower as an ingredient [28,32]. Recently, topical dosage forms of wallflower has been suggested for clinical skin diseases [26]. According to new in vitro/ in vivo pharmacological studies, cardiac steroids in low doses (below their IC₅₀) have shown stimulatory effects on Na⁺/K⁺ ATPase pumps that occurs in safe dose below their minimum toxic concentrations [52-54]. Therefore, dose adjustment of wallflower products are necessary in order to decrease side effects of probable cardenolide constituents. It is suggested that IC₅₀ value of cardenolide extract from the whole product could be a good criteria to evaluate safety of wallflower preparations. For

this purpose, IC_{50} value of an extract of wallflower product could be compared with IC_{50} value of a known cardiac steroid (for example digoxin) as an indicator. On the other hand, cardenolide's amount fraction could be estimated

according to HPTLC-densitometry calibration curve to a standard cardiac steroid (e.g. digoxin). This method may provide information about safety degree of wallflower traditional products.

Terpenoides → Cardiac steroids

Group of "Strophanthidin"




(1) 3-*O*-[β -D-Glucopyranosyl-(1→4)-6-deoxy- β -D-glucopyranoside]

(2) 3-*O*-(6-Deoxy- β -D-glucopyranoside)

(3) 3-*O*-[β -D-Glucopyranosyl-(1→4)-2,6-dideoxy- β -D-ribo-hexopyranoside]

(4) 3-*O*-[β -D-Glucopyranosyl-(1→4)- β -D-glucopyranosyl-(1→4)-2,6-dideoxy- β -D-ribo-hexopyranoside]

Group of "Bipindogenin"




(5) 3-*O*-(6-Deoxy- α -L-glucopyranoside)

(6) 3-*O*-[3-*O*-Methyl- β -D-glucopyranosyl-(1→4)-6-deoxy- α -L-glucopyranoside]

(7) 3-*O*-[β -D-Rhamnopyranosyl-(1→4)- β -D-glucopyranoside]

Figure 1. Chemical structure of natural compounds in wallflower (see table 1)


Group of "Uzarigenin"



(8) 3-*O*-[β-D-Glucopyranosyl-(1→4)-β-D-fucopyranoside]


(9) 3-*O*-[β-D-Glucopyranosyl-(1→4)-β-D-glucopyranoside]

Group of "Cannogenol"




(10) 3-*O*-[β-D-Glucopyranosyl-(1→4)-6-deoxy-β-D-glucopyranoside]

Group of "Digitoxigenin"



(11) 3-*O*-[β-D-Glucopyranosyl-(1→4)-β-D-glucopyranosyl-(1→4)-β-D-fucopyranoside]

Monoterpenoids




3,7-Dimethyl-2,6-octadien-1-ol (C₁₀H₁₈O)

(12) (*E*) form: Geraniol


(13) (*Z*) form: Nerol

Figure 1. Continued




(14) (R) form: Linalool

Flavonoids




(15) Isorhamnetin (C₁₆H₁₂O₇)

(16) Isorhamnetin: 3-*O*- α -L-Arabinopyranoside, 7-*O*- α -L-rhamnopyranoside



(17) Kaempferol (C₁₅H₁₀O₆)

Cyanidins




(18) (*E*) derivative:

3-*O*-[β -D-Xylopyranosyl-(1 \rightarrow 2)-[4-hydroxy-*E*-cinnamoyl-(\rightarrow 6)]- β -D-glucopyranoside],
5-*O*- β -D-glucopyranoside


(*Z*) derivative:

3-*O*-[β -D-Xylopyranosyl-(1 \rightarrow 2)-[4-hydroxy-*Z*-cinnamoyl-(\rightarrow 6)]- β -D-glucopyranoside],
5-*O*- β -D-glucopyranoside


Minor phenylpropanoids:



(19) Anis aldehyde (C₈H₈O₂)




(20) Benzyl alcohol (C₇H₈O)




(21) Salicylic acid (C₇H₆O₃)


Glucosinolates and isothiocyanates




(22) Cheiroline (C₅H₉NO₂S₃)



(24) Iberin (C₅H₉NOS₂)




(23) Glucocheirolin (C₁₁H₂₁NO₁₁S₃)




(25) Glucoiberin (C₁₁H₂₁NO₁₀S₃)


Figure 1. Continued

(26) Ibervirin (C₅H₉NS₂)


Miscellaneous nitrogen-containing structures




(27)

(28) Anthranilic acid (C₇H₇NO₂)


Aliphatics




(29)




(30)



(31)



(32)



(33)

Figure 1. Continued

Acknowledgments

This study was supported by a grant (95-01-05-11993) from Shiraz University of Medical Sciences. This study was part of the Ph.D thesis of Ghazaleh Mosleh. The authors would like to thank the vice chancellor of research and the research and consultation center in Shiraz University of Medical Sciences for their contributions to this study and editing the manuscript.

Author contributions

Ghazaleh Mosleh contributed as Ph.D. student and the main study investigator; Amir Azadi, Parmis Badr, Zohreh Abolhassanzadeh, Seyed Vahid Hosseini and Abdolali Mohagheghzadeh contributed as supervisors of the whole project. All authors approved the final draft of the manuscript.

Declaration of interest

The authors declare that there is no conflict of interest. The authors alone are responsible for the content of the paper.

References

- [1] The plant list. *Erysimum × cheiri* (L.) Crantz. [Accessed 2018]. Available from: <http://www.theplantlist.org/tpl1.1/record/kew-2799915>.
- [2] Missouri Botanical Garden, St. Louis, MO & Harvard University Herbaria, Cambridge, MA. *Cheiranthus cheiri* Linn. flora of Pakistan. [Accessed 2018]. Available from: http://www.efloras.org/florataxon.aspx?flora_id=5&taxon_id=200009360.
- [3] Erum A, Aslam M, Jafri MA, Ahmed MA, Yousuf AW. Phytochemical and ethnopharmacological review of “Tudri

- surkh" (*Cheiranthus cheiri*). *World J Pharm Res.* 2017; 6(5): 352-359.
- [4] Fleming Th. PDR for herbal medicines. Montvale: Medical Economics Company, 2000.
- [5] Mutlu B. New morphological characters for some *Erysimum* (Brassicaceae) species. *Turk J Bot.* 2010; 34(1): 115-121.
- [6] Rhazi M. Al hawi [liber continent]. Trans. Afsharipour S. 1st ed. Tehran: Academy of Medical Sciences Publication, 2005.
- [7] Avicenna. The Canon of medicine. Trans. by Sharafkandi A. 2nd ed. Tehran: Soroush Press, 1997.
- [8] Tonkaboni MM. Tohfeh al- momenin. 1st ed. Rahimi R, Shams Ardekani MR, Farjadmand F, Eds. Tehran: Shahid Beheshti University of Medical Sciences, 2007.
- [9] Aghili MH. Makhzan-al-advia. Shams Ardakani MR, Rahimi R, Farjadmand F, Eds. Tehran: Tehran University of Medical Sciences Publication, 2009.
- [10] Nazem Jahan MA. Mohit-e azam. Tehran: Almai Publication, 2015.
- [11] Gharashi A. (Ibne-nafis). Alshamel-fi alsanaat altebya. Tehran: Iran University of Medical Sciences Publication, 2008.
- [12] Ghassani A. Hadiqat ol-azhar fi sharh maziyat al-oshb val aqqar. Tehran: Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, 2008.
- [13] Taylor & Francis Group. *Cheiranthus cheiri*. The dictionary of natural products. [Accessed 2011]. Available from: <http://dnp.chemnetbase.com/>.
- [14] Reeb M. *Cheiranthus cheiri*. *Arch Exp Pathol U Pharm.* 1898; 41(1); 302.
- [15] Reeb M. Active constituents of the wallflower. *J Chem Soc Abstr.* 1900; 78: 186.
- [16] Anderson T. The plant alkaloids. London: J. & A. Churchill Ltd, 1949.
- [17] American druggist and pharmaceutical record. Cheiranthin. [Accessed 2018]. Available from: https://archive.org/stream/american-druggist-31-unkn-goog/american-druggist-31-unkn-goog_djvu.txt.
- [18] Schultz OE, Gmelin R. Papierchromatographie senfölglicosidhaltiger pflanzen neue ergebnisse. *Z Naturforsch B.* 1953; 8(3): 151-156.
- [19] Cheirolin, the tiocarbimide in wallflower seeds. Its synthesis and degradation. *J Chem Soc Abstr.* 1910; 98(1): 658-660.
- [20] Schneider W, Lohmann W. Thiocarbimides: the glucoside of Cheirolin. *Org Chem.* 1912; 102(933-1044): 1007-1008.
- [21] Gildemeister E. The volatile oils. New York: John Wiley and Sons, 1916.
- [22] Jaretsky R. Cardiac glucosides of *Cheiranthus cheiri* and related species. *Br Chem Abstr.* 1932; 1(1): 541.
- [23] Anders K, Franz M, Josef C. Isothiocyanates. VI. A synthesis of cheirolin (gamma-methylsulphonyl propyl isothiocyanate). *Acta Chem Scand.* 1953; 7(1): 1370-1374.
- [24] Moore J, Tamm Ch, Reichstein T. Die glykoside der goldlacksamen, *Cheiranthus cheiri* L. *Helv Chim Acta.* 1954; 37(1): 755-770.
- [25] Makarevich IF, Slyusarskaya TV, Yarmolenko GN. Cardenolide-containing plants of the family Cruciferae. *Chem Nat Compd.* 1994; 30(3): 275-289.
- [26] Saleem M, Alam A, Sultana S. *Cheiranthus cheiri* abrogates phorbol ester induced tumor promotion response in murine skin. *Pharm Biol.* 2001; 39(1): 25-34.
- [27] Tatsuzawa F, Saito N, Shinoda K, Shigihara A, Honda T. Acylated cyanidin 3-sambubioside-5-glucosides in three garden plants of the Cruciferae. *Phytochemistry.* 2006; 67(12): 1287-1295.
- [28] Iranhelsa. Anti-fissure ointment. [Accessed 2018]. Available from: <http://www.iranhelsa.com>.
- [29] Luqman clinics. Doodhi tablets. [Accessed 2018]. Available from: <http://www.luqmanclinic.com>.
- [30] Netland KE, Martinez J. Abortifacients: toxidromes, ancient to modern-a case series and review of the literature. *Acad Emerg Med.* 2000; 7(7): 824-829.

- [31] Khare CP. Indian medicinal plants, an illustrated dictionary. New York: Springer, 2007.
- [32] Athar M, Siddiqi M. Reflections on the taxonomy and distribution of medicinal flowers of Pakistan. *Sida Contrib Bot.* 2004; 21(1): 357-368.
- [33] Evans WC, Evans D, Trease GE. Trease and Evans' pharmacognosy. Edinburgh: WB Saunders, 2002.
- [34] Junghans T. Der goldlack - zier- und nutzpflanze auf abwege. *Pharmu Z.* 2010; 39(4): 322.
- [35] European food safety authority (EFSA). Compendium of botanicals reported to contain naturally occurring substances of possible concern for human health when used in food and food supplements. *EFSA J.* 2012; 10(5): 1-60.
- [36] Vaughn SF, Berhow MA. Glucosinolate hydrolysis products from various plant sources: pH effects, isolation, and purification. *Ind Crops Prod.* 2005; 21(2): 193-202.
- [37] Azimova SS, Glushenkova AI, Vinogradova VI. Lipids, lipophilic components and essential oils from plant sources. London: Springer-Verlag, 2012.
- [38] Lawrence WJC, Price JR, Robinson GM, Robinson R. The distribution of anthocyanins in flowers, fruits and leaves. *Phil Trans R Soc Lond B.* 1939; 230(567): 149-178.
- [39] Arnold Ä. Goldlack- *Erysimum cheiri*. [Accessed 2017]. Available from: http://www.awl.ch/heilpflanzen/erysimum_cheiri/goldlack.htm.
- [40] Willaman J, Schubert B. Alkaloid-bearing plants and their contained alkaloids. Washington: Dept. of Agriculture, the University of Virginia, 1961.
- [41] Schmidt RJ. Wallflower. [Accessed 2016]. Available from: <http://www.botanical-dermatology-database.info/BotDermFolder/CRUC.html>.
- [42] Services PP. *Cheiranthus cheiri* Linn. [Accessed 2017]. Available from: <http://www.druginfosys.com/herbal/herb.aspx?code=143&name=cheiranthus%20cheiri%20linn.&type=1>.
- [43] Mircea C. Allergenic and toxic compounds in ornamental plants- a review. *Bull UASVM Hort.* 2014; 71(2): 180-184.
- [44] Wink M. Mode of action and toxicology of plant toxins and poisonous plants. *Julius Kühn Archiv.* 2009; 421(1): 93-112.
- [45] Bachelard H, Tricojus VM. Plant thioglycosides and the problem of endemic goiter in Australia. *Nature.* 1960; 185(1): 80-82.
- [46] LKT Laboratories. "Cheirolin, 97%". [Accessed 2017]. Available from: http://www.lktlabs.com/products/Cheirolin_97-52-60.html.
- [47] Haristoy X, Fahey JW, Scholtus I, Lozniewski A. Evaluation of the antimicrobial effects of several isothiocyanates on *Helicobacter pylori*. *Planta Med.* 2005; 71(4): 326-330.
- [48] Ew W. Cheiranthin, an active constituent of the wallflower. *Org Chem.* 1899; 378-379.
- [49] Kaul B, Wells P, Staba ES. Production of cardioactive substances by plant tissue cultures and their screening for cardiovascular activity. *J Pharnz Pharmac.* 1967; 19(11): 760-766.
- [50] Senthilkumaran S, Saravanakumar S, Thirumalaikolundusubramanian P. Cutaneous absorption of Oleander: fact or fiction. *J Emerg Trauma Shock.* 2009; 2(1): 43-45.
- [51] Groves MJ, Bisset NG. A note on the use of topical digitalis prior to William Withering. *J Ethnopharmacol.* 1991; 35(2): 99-103.
- [52] El-Okdi N, Smaili S, Raju V, Shidyak A, Gupta S, Fedorova L, Elkareh J, Periyasamy S, Shapiro AP, Kahaleh MB, Malhotra D, Xie Z, Chin KV, Shapiro JI. Effects of CTS on dermal collagen synthesis and wound healing. *J Appl Physiol.* 2008; 105(1): 30-36.
- [53] Oselkin M, Tian D, Bergold PJ. Low-dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia. *Neurosci Lett.* 2010; 473(2): 67-71.
- [54] Mosleh Gh, Badr P, Abolhassanzadeh Z, Hosseini SV, Mohagheghzadeh A, Azadi A. Potential effects and mechanisms of action of topical wallflower (*Erysimum cheiri* (L.)

Cranz) administration in anal fissure. *Res J Pharmacogn.* In press.

Abbreviations

PM: Persian medicine; IC₅₀: Inhibitory concentration 50